Johnson & Johnson Cash Flow Statement
NYSE: JNJHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Johnson & Johnson free cash flow
In fiscal 2025, Johnson & Johnson generated $24.53 billion of operating cash flow and spent $4.83 billion on capital expenditures. That left free cash flow of $19.70 billion, a free-cash-flow margin of 20.9% of revenue. Free cash flow was down 0.7% from the prior year's $19.84 billion.
Johnson & Johnson returned $18.33 billion to shareholders: $12.38 billion in dividends and $5.95 billion in share repurchases, equal to 93% of free cash flow. Free cash flow covered dividend payments 1.6 times.
Summary generated from market data by MetaCap's automated system. Methodology
Johnson & Johnson cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-28 | FY 20242024-12-29 | FY 20232023-12-31 | FY 20222023-01-01 | FY 20212022-01-02 | FY 20202021-01-03 | FY 20192019-12-29 | FY 20182018-12-30 | FY 20172017-12-31 | FY 20162017-01-01 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 26.80B | 14.07B | 35.15B | 17.94B | 20.88B | 14.71B | 15.12B | 15.30B | 1.30B | 16.54B |
| Net Income growth (YoY) | +90.56% | -59.99% | +95.94% | -14.07% | +41.89% | -2.68% | -1.16% | +1076.69% | -92.14% | +7.34% |
| Depreciation & Amortization | 7.50B | 7.34B | 7.49B | 6.97B | 7.39B | 7.23B | 7.01B | 6.93B | 5.64B | 3.75B |
| Stock-Based Compensation | 1.35B | 1.18B | 1.16B | 1.14B | 1.14B | 1.00B | 977.00M | 978.00M | 962.00M | 878.00M |
| Change in Working Capital | -12.72B | 1.84B | 2.51B | -4.01B | -4.24B | 2.69B | 3.87B | 3.00M | 11.24B | -1.77B |
| Operating Cash Flow | 24.53B | 24.27B | 22.79B | 21.19B | 23.41B | 23.54B | 23.42B | 22.20B | 21.06B | 18.77B |
| Capital Expenditures | -4.83B | -4.42B | -4.54B | -4.01B | -3.65B | -3.35B | -3.50B | -3.67B | -3.28B | -3.23B |
| Investing Cash Flow | -23.59B | -18.60B | 878.00M | -12.37B | -8.68B | -20.82B | -6.19B | -3.17B | -14.87B | -4.76B |
| Dividends Paid | -12.38B | -11.82B | -11.77B | -11.68B | -11.03B | -10.48B | -9.92B | -9.49B | -8.94B | -8.62B |
| Share Repurchases | -5.95B | -2.43B | -5.05B | -6.04B | -3.46B | -3.22B | -6.75B | -5.87B | -6.36B | -8.98B |
| Debt Issued | 9.14B | 6.66B | 0 | 2.00M | 5.00M | 7.43B | 3.00M | 5.00M | 8.99B | 12.00B |
| Debt Repaid | -1.76B | -1.45B | -1.55B | -2.13B | -1.80B | -1.06B | -2.82B | -1.55B | -1.78B | -2.22B |
| Financing Cash Flow | -5.54B | -3.13B | -15.82B | -8.87B | -14.05B | -6.12B | -18.02B | -18.51B | -7.67B | -8.55B |
| Net Change in Cash | -4.40B | 2.25B | 7.73B | -360.00M | 502.00M | -3.32B | -802.00M | 283.00M | -1.15B | 5.24B |
| Free Cash Flow | 19.70B | 19.84B | 18.25B | 17.18B | 19.76B | 20.19B | 19.92B | 18.53B | 17.78B | 15.54B |
This table shows 10 annual periods of Johnson & Johnson's cash flow statement, from FY 2025 back to FY 2016, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow JNJ's reporting calendar. What is a cash flow statement?